"Etanercept" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A recombinant version of soluble human TNF receptor that binds specifically to TUMOR NECROSIS FACTOR and inhibits its binding with endogenous TNF receptors. It prevents the inflammatory effect of TNF and is used to treat RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS and ANKYLOSING SPONDYLITIS.
| Descriptor ID |
D000068800
|
| MeSH Number(s) |
D12.776.124.486.485.114.619.393.261 D12.776.124.790.651.114.619.393.261 D12.776.377.715.548.114.619.393.261 D12.776.543.750.705.852.760.232
|
| Concept/Terms |
TNFR-Fc Fusion Protein- TNFR-Fc Fusion Protein
- Fusion Protein, TNFR-Fc
- Protein, TNFR-Fc Fusion
- TNFR Fc Fusion Protein
- TNR-001
- TNR001
- TNR 001
- 001, TNR
- TNT Receptor Fusion Protein
- TNTR-Fc
|
Below are MeSH descriptors whose meaning is more general than "Etanercept".
Below are MeSH descriptors whose meaning is more specific than "Etanercept".
This graph shows the total number of publications written about "Etanercept" by people in this website by year, and whether "Etanercept" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 3 | 3 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 3 | 3 |
| 2005 | 0 | 3 | 3 |
| 2006 | 0 | 2 | 2 |
| 2008 | 0 | 4 | 4 |
| 2009 | 0 | 5 | 5 |
| 2010 | 0 | 3 | 3 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 3 | 3 |
| 2017 | 1 | 2 | 3 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Etanercept" by people in Profiles.
-
Interaction between tumor cell TNFR2 and monocyte membrane-bound TNF-a triggers tumorigenic inflammation in neuroblastoma. J Immunother Cancer. 2023 03; 11(3).
-
Fecal microbiota in children with juvenile idiopathic arthritis treated with methotrexate or etanercept. Pediatr Rheumatol Online J. 2021 Apr 26; 19(1):55.
-
Important determinants of the patient choice between TNF- vs. non-TNF Biologic disease-modifying anti-rheumatic drugs (DMARDs) for active rheumatoid arthritis (RA). Joint Bone Spine. 2020 07; 87(4):307-313.
-
Etanercept With IVIg for Acute Kawasaki Disease: A Randomized Controlled Trial. Pediatrics. 2019 06; 143(6).
-
Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol. 2019 01; 71(1):5-32.
-
Anti TNF-a therapy in patients with relapsed and refractory Langerhans cell histiocytosis: a phase II study. Pediatr Hematol Oncol. 2018 Aug - Sep; 35(5-6):362-368.
-
Comparative Effectiveness of Tumor Necrosis Factor Agents and Disease-modifying Antirheumatic Therapy in Children with Enthesitis-related Arthritis: The First Year after Diagnosis. J Rheumatol. 2018 01; 45(1):107-114.
-
Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome. Biol Blood Marrow Transplant. 2017 Nov; 23(11):1955-1960.
-
Lymphatic delivery of etanercept via nanotopography improves response to collagen-induced arthritis. Arthritis Res Ther. 2017 05 31; 19(1):116.
-
Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2017 05 08; 5:CD012657.